Discover Hope for Rhabdomysarcoma's Information Services

These treatments are usually performed after the primary care but sometimes they are performed in combination with primary care. Many of these treatments are in early stages of trials and have certain criteria the patient must meet such as age, health and other factors.  

• Targeted Chemotherapy Combinations:
  • Adding temozolomide to standard vincristine/irinotecan regimens for relapsed or high-risk RMS shows promise in trials.
  • Exploring newer drugs like irinotecan, which shows activity in pediatric sarcomas.
• Immunotherapy:
  • Combining immunotherapy, such as pembrolizumab, with radiation and surgery significantly improved cancer-free survival in high-risk soft tissue sarcomas, suggesting a new approach for RMS.
• Advanced Radiation Techniques:
  • Surface-Guided Radiation Therapy (SGRT) and gating/tracking offer       enhanced precision, minimizing damage to healthy tissues by monitoring tumor movement in real-time.
• Molecular-Driven Approaches:
  • Research       is focusing on understanding RMS's unique molecular features (genomics)       to identify specific targets for new drugs.
• Combination Trials:
  • Studies are testing feasibility and effectiveness of adding drugs like cixutumumab (a       monoclonal antibody) with intensive chemo for metastatic RMS. 

In Canada, pembrolizumab is not specifically approved by Health Canada for the treatment of rhabdomyosarcoma (RMS), but it is being investigated in clinical trials for certain soft tissue sarcomas, including a potential trial involving related poorly differentiated sarcomas. 

CAR-T THERAPY  Key Aspects of CAR T-Cell Therapy for Rhabdomyosarcoma

• Targeting FGFR4: Research focuses on targeting fibroblast growth factor receptor 4 (FGFR4), a protein highly expressed in rhabdomyosarcoma, using engineered CAR T-cells.
• Targeting CD276 (B7-H3): Studies are also exploring CD276, another surface protein highly expressed in RMS, to improve treatment efficacy.
• Dual-Targeting Approaches: Advanced studies are investigating dual-CAR T cells that target both FGFR4 and CD276 to overcome tumor heterogeneity and improve durability.
• Clinical Trials: A phase I dose-escalation study is active at the NIH Clinical Center for children and young adults (ages 3–39) with relapsed/refractory RMS, involving chemotherapy to prepare for CAR T-cell infusion.
• Preclinical Success: Studies in mice have shown that FGFR4-targeted CAR T cells can eliminate solid RMS tumors.
• Treatment Process: The process involves collecting the patient's T cells, genetically engineering them in a lab to target the cancer, multiplying them, and infusing them back into the patient.
• Challenges: While effective in preclinical models, the main challenges are navigating the immunosuppressive tumor environment and ensuring persistent anti-tumor activity. National Cancer Institute (.gov) +6